-
Mashup Score: 0Second-Generation Bruton's Tyrosine Kinase Inhibitors: Simply the Best Treatments for Chronic Lymphocytic Leukemia? - 3 year(s) ago
Ibrutinib is the oral, covalently binding inhibitor of Bruton’s tyrosine kinase (BTK) that revolutionized therapy for patients with chronic lymphocytic leukemia (CLL). Ibrutinib’s significant efficacy and enhanced tolerability compared with standard chemoimmunotherapy regimens were driving factors in the shift to targeted therapies as the preferred CLL treatment option for most patients.1-3 For a…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
@RahulBanerjeeMD @RahulBanerjeeMD you’re indeed Babis’s mentee!! I highly recommend Dr. @DebbieMStephens fantastic commentary on this topic: https://t.co/NMf60ZlKg4